Filter by Topic
Preimplantation genetic diagnosis (PGD) involves testing for specific genetic conditions prior to the implantation of an embryo in the uterine wall. This form of genetic screening has been made possible by the growth of in-vitro fertilization (IVF) technology, which allows for the early stages of development to occur in a laboratory dish rather than in vivo. The purpose of PGD is to identify what are considered to be abnormal embryos in order to select the most desirable embryos for implantation.
Plan B is a progestin-only emergency contraceptive pill (ECP) that can be taken within seventy-two hours of unprotected sex in order to prevent an unwanted pregnancy. Plan B was created in response to the United States Food and Drug Administration's (US FDA) 1997 request for new drug applications (NDAs) for a dedicated ECP product, and was approved for sales in the US in 1999. Duramed, a subsidiary of Barr Pharmaceuticals, manufactures Plan B for The Women's Capital Corporation (WCC), which owns the patent for Plan B.
Throughout history many different methods have been devised for the early detection of pregnancy. From the time of the Ancient Egyptians, inspection of the urine has been a popular place to start. However, it was not until the discovery of hormones in the early twentieth century that the development of truly reliable pregnancy tests occurred. Prior to 1978, when the first home pregnancy tests became available in the United States, pregnancy testing was done in hospital laboratories using various methods, one of them being the Aschheim-Zondek, or A-Z test.